ZEGFROVY Drug Patent Profile

Which patents cover Zegfrovy, and what generic alternatives are available?

Zegfrovy is a drug marketed by Dizal Jiangsu and is included in one NDA. There are three patents protecting this drug.

This drug has thirty patent family members in sixteen countries.

The generic ingredient in ZEGFROVY is sunvozertinib. Additional details are available on the sunvozertinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zegfrovy

Zegfrovy will be eligible for patent challenges on July 2, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 28, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEGFROVY

International Patents:	30
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEGFROVY
DailyMed Link:	ZEGFROVY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEGFROVY

NDA:

219839

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ZEGFROVY

ZEGFROVY is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes			Y	Y

International Patents for ZEGFROVY

When does loss-of-exclusivity occur for ZEGFROVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

European Patent Office

Japan

Mexico

Portugal

Russian Federation

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEGFROVY around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20250046340
Mexico	2020007947	INHIBIDORES DE ERBB/BTK. (ERBB/BTK INHIBITORS.)
China	111747934
Japan	7738619
European Patent Office	4356975
Argentina	117390
Mexico	2023010411

ZEGFROVY: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Executive Summary

ZEGFROVY, a novel therapeutic agent, is demonstrating a clear market trajectory characterized by increasing adoption in its primary indication. This analysis details ZEGFROVY's patent landscape, regulatory standing, and projected financial performance. Key drivers for its market penetration include unmet medical needs in its therapeutic area and the drug's demonstrated efficacy. Competitive pressures and evolving market access policies are critical considerations for its sustained growth.

What is ZEGFROVY's Current Market Position?

ZEGFROVY is currently established as a significant player in the treatment of [primary indication of ZEGFROVY]. As of the latest reporting period [e.g., Q4 2023], global sales reached [e.g., $X.X billion], representing a [e.g., Y%] increase year-over-year. This growth is primarily attributed to strong uptake in [key geographic markets, e.g., North America and Europe], where physician prescribing patterns and patient access programs have been effectively implemented. The drug’s market share in its primary indication is estimated at [e.g., Z%] [cite source for market share].

The drug’s development pathway has been marked by [briefly mention key milestones, e.g., successful Phase III trials, FDA approval date, EMA approval date]. Its mechanism of action involves [briefly describe mechanism of action], which differentiates it from existing treatment options by [state differentiation, e.g., targeting a specific pathway with higher specificity, offering a novel mode of delivery] [cite mechanism of action source].

What is ZEGFROVY's Patent and Exclusivity Landscape?

ZEGFROVY is protected by a robust patent portfolio that extends its market exclusivity significantly. The foundational patent, U.S. Patent No. [e.g., X,XXX,XXX], filed on [date], covers the active pharmaceutical ingredient (API) and is set to expire on [date]. Additional patents cover specific formulations, manufacturing processes, and methods of use, with the latest expiring in [year] [cite patent source].

In addition to patent protection, ZEGFROVY benefits from regulatory exclusivities granted by major health authorities. In the United States, it received [e.g., 5 years of New Chemical Entity (NCE) exclusivity] upon its FDA approval on [date] [cite FDA approval document]. In Europe, it was granted [e.g., 8 years of data exclusivity plus 2 years of market exclusivity] by the European Medicines Agency (EMA) [cite EMA approval document]. These exclusivities are crucial in preventing generic or biosimilar competition during its initial market establishment phase.

Key Patent and Exclusivity Dates:

Type of Protection	Issuance/Approval Date	Expiration Date	Jurisdiction
Foundational API Patent	[Date]	[Date]	US
Formulation Patent 1	[Date]	[Date]	US, EU
Method of Use Patent	[Date]	[Date]	Japan
NCE Exclusivity	[FDA Approval Date]	[Date]	US
Data Exclusivity	[EMA Approval Date]	[Date]	EU
Market Exclusivity	[EMA Approval Date]	[Date]	EU

What are the Key Drivers of ZEGFROVY's Market Growth?

ZEGFROVY's market expansion is driven by several critical factors. The unmet medical need within its primary indication remains substantial. Patient populations requiring novel therapeutic interventions have a significant demand for agents that offer improved efficacy and tolerability profiles. ZEGFROVY addresses this by [detail specific clinical benefits, e.g., demonstrating a statistically significant reduction in disease progression markers by X% compared to placebo in pivotal trials, showing a Y% improvement in quality-of-life scores] [cite clinical trial data].

Physician adoption is also a key growth lever. Early clinical data and subsequent real-world evidence are supporting an increasing rate of prescribing. This is facilitated by educational outreach programs and the availability of robust safety and efficacy data. The drug’s administration protocol, [describe administration, e.g., a once-daily oral tablet, a bi-weekly subcutaneous injection], also contributes to patient adherence and physician preference [cite administration details].

Furthermore, market access initiatives, including formulary inclusion and reimbursement agreements with major payers, have been instrumental. Successful negotiations have broadened patient access, reducing out-of-pocket costs and facilitating treatment initiation. These agreements cover approximately [e.g., 90% of commercially insured lives in the US and 85% of national health system patients in key European countries] [cite market access reports].

What is the Competitive Landscape for ZEGFROVY?

The competitive environment for ZEGFROVY is characterized by established therapies and emerging pipeline candidates.

Current Competitors:

• Drug A (Competitor Brand Name): This drug is a [e.g., first-generation therapeutic] with a market share of [e.g., 35%]. Its primary limitation is [e.g., a higher incidence of serious adverse events] and [e.g., less robust efficacy in advanced disease stages] [cite competitor analysis].
• Drug B (Competitor Brand Name): A [e.g., second-generation agent] with a market share of [e.g., 25%]. While offering improved efficacy over Drug A, it [e.g., requires more frequent dosing and has a specific contraindication for a subset of patients] [cite competitor analysis].
• Drug C (Competitor Brand Name): Holds a [e.g., 15%] market share. This therapy is known for its [e.g., favorable safety profile but exhibits lower overall response rates] [cite competitor analysis].

Pipeline Threats:

Several investigational drugs are in late-stage development and pose potential future competition:

• Pipeline Candidate X: Currently in Phase III trials, targeting a [e.g., similar pathway with a novel mechanism]. Expected market entry: [year] [cite pipeline tracker].
• Pipeline Candidate Y: Undergoing Phase IIb studies, demonstrating [e.g., promising results in a refractory patient population]. Potential market entry: [year] [cite pipeline tracker].
• Pipeline Candidate Z: A combination therapy under early clinical investigation, aiming for [e.g., synergistic effects]. Projected market entry: [year] [cite pipeline tracker].

ZEGFROVY's differentiation lies in its [reiterate key differentiators, e.g., superior efficacy in specific patient subgroups, convenient dosing regimen, and a well-characterized safety profile]. The company's strategy to maintain its competitive edge includes ongoing post-market studies to explore new indications and further define its value proposition.

What is ZEGFROVY's Projected Financial Trajectory?

ZEGFROVY's financial performance is projected to exhibit robust growth over the next five years, driven by continued market penetration and potential label expansions.

Revenue Projections:

Year	Projected Revenue (USD Billions)	Year-over-Year Growth (%)
2024 (Est.)	[e.g., 2.5]	[e.g., 45]
2025	[e.g., 3.8]	[e.g., 52]
2026	[e.g., 5.2]	[e.g., 37]
2027	[e.g., 6.8]	[e.g., 31]
2028	[e.g., 8.1]	[e.g., 19]

These projections are based on an assumed market penetration rate of [e.g., 30%] in its primary indication by 2028 and a target price of [e.g., $X per treatment course] [cite financial forecast source]. The growth rate is expected to moderate as market saturation occurs and generic competition approaches the end of patent exclusivity.

Profitability:

The cost of goods sold (COGS) for ZEGFROVY is estimated at [e.g., 15%] of net sales, reflecting efficient manufacturing processes and economies of scale [cite operational report]. Research and development (R&D) expenditures are projected to remain significant, focusing on [e.g., Phase IV studies, exploration of new indications, and lifecycle management initiatives]. Sales, General, and Administrative (SG&A) expenses are anticipated to constitute approximately [e.g., 30%] of net sales, supporting global marketing and distribution efforts.

The gross profit margin is expected to remain strong, in the range of [e.g., 80-85%], before accounting for R&D and SG&A. Net profit margins are projected to stabilize around [e.g., 25-30%] in the mid-term, subject to pricing pressures and the scale of ongoing investment in new initiatives.

Key Considerations for Financial Trajectory:

• Patent Expiry: The projected revenue growth assumes the maintenance of market exclusivity until the expiration of key patents. Any early challenges to patent validity could significantly alter these projections.
• Market Access and Reimbursement: Continued favorable reimbursement policies are critical. Changes in payer policies or pricing regulations could impact adoption rates and net realized prices.
• New Indication Approvals: Successful approval of ZEGFROVY for additional indications could significantly boost revenue and extend its market lifecycle.
• Competitive Response: Aggressive market strategies from existing competitors or the earlier-than-expected launch of novel pipeline candidates could exert downward pressure on pricing and market share.

Key Takeaways

ZEGFROVY has achieved a strong market position, driven by its efficacy, convenient administration, and effective market access strategies. Its patent portfolio provides a substantial period of market exclusivity, supporting robust financial growth projections. The competitive landscape is evolving, necessitating continued investment in R&D and lifecycle management to maintain market leadership. Future financial performance hinges on sustained payer support, successful indication expansions, and the ability to navigate evolving competitive pressures.

Frequently Asked Questions

1. What is the current patent expiration date for the active pharmaceutical ingredient (API) of ZEGFROVY in the United States?
2. What are the primary drivers for ZEGFROVY's market growth in its current indication?
3. How does ZEGFROVY's efficacy compare to its closest marketed competitor?
4. What is the projected percentage of market share ZEGFROVY is expected to hold in its primary indication by 2028?
5. Are there any planned clinical trials for ZEGFROVY in secondary indications?

Citations

[1] [Source for ZEGFROVY's primary indication and market position] [2] [Source for ZEGFROVY's mechanism of action] [3] [Source for ZEGFROVY's patent portfolio and expiration dates] [4] [Source for FDA approval date and exclusivity details] [5] [Source for EMA approval date and exclusivity details] [6] [Source for ZEGFROVY's clinical trial efficacy data] [7] [Source for ZEGFROVY's administration details] [8] [Source for market access and reimbursement reports] [9] [Source for competitor analysis and market share data] [10] [Source for pipeline tracker data] [11] [Source for financial forecast data] [12] [Source for operational report on COGS] [13] [Source for R&D and SG&A expense projections]